Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

OBJECTIVE: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine storm”. Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the ai...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Virol
Главные авторы: Quartuccio, Luca, Sonaglia, Arianna, McGonagle, Dennis, Fabris, Martina, Peghin, Maddalena, Pecori, Davide, De Monte, Amato, Bove, Tiziana, Curcio, Francesco, Bassi, Flavio, De Vita, Salvatore, Tascini, Carlo
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier B.V. 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227535/
https://ncbi.nlm.nih.gov/pubmed/32570043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcv.2020.104444
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы